Company reports rapid commercial growth, reaches customers in 19 countries, and prepares for next phase of innovation with EMA submission and SPECT acquisition

公司报告商业增长迅速，已覆盖19个国家的客户，并通过EMA提交和SPECT收购为下一阶段的创新做好准备。

JANESVILLE, Wis.

简斯维尔，威斯康星州

,

，

June 20, 2025

2025年6月20日

/PRNewswire/ -- SHINE Technologies, a nuclear fusion company with a platform in medical isotope products, announced a year of exceptional growth and strategic expansion as Ilumira™ (n.c.a. lutetium-177) marks its first anniversary in the global marketplace. Since launching in

/PRNewswire/ -- SHINE科技公司，一家在医疗同位素产品领域拥有平台的核聚变公司，宣布了一年的非凡增长和战略扩张，其产品Ilumira™（无载体添加的镥-177）在全球市场迎来了上市一周年。自推出以来

June 2024

2024年6月

, Ilumira has delivered strong commercial growth, shipped to 19 countries, and achieved over 95% on-time, in-full delivery – all while expanding its distribution network across

，Ilumira实现了强劲的商业增长，产品已运往19个国家，并达成了超过95%的准时、完整交货率——同时还在不断扩展其分销网络。

Asia

亚洲

,

，

Europe

欧洲

,

，

Australia

澳大利亚

, and the

，以及

Middle East

中东地区

.

。

Ilumira Lights the Way for Cancer Therapy

照亮癌症治疗之路

SHINE celebrates Ilumira's first anniversary with strong commercial growth, global expansion, and strategic moves including EMA submission and SPECT acquisition positioning for nuclear medicine leadership.

SHINE庆祝了Ilumira成立一周年，公司在商业增长、全球扩张以及包括EMA提交和SPECT收购等战略举措上取得显著成绩，进一步巩固了其在核医学领域的领导地位。

Ilumira is reliable, high-quality n.c.a. lutetium-177 that is made in the US from start to finish.

Ilumira 是一种从头到尾都在美国制造的可靠、高质量的非载体添加镥-177。

Ilumira is the game-changer in cancer therapy. We're the only U.S. manufacturer with a reliable, weekly supply of high-quality Lu-177, produced right here in Wisconsin.

Ilumira 是癌症治疗的变革者。我们是唯一一家在美国生产高质Lu-177的制造商，每周都能提供可靠供应，且就在威斯康星州本地生产。

Our advanced production process ensures unmatched purity and efficacy, exceeding international standards for reliable supply.

我们先进的生产流程确保了无与伦比的纯度和功效，超越了国际标准，供应可靠。

SHINE's Ilumira is produced in the company's Cassiopeia facility in Janesville, Wisconsin.

SHINE的Ilumira是在其位于威斯康星州简斯维尔的卡西奥佩亚工厂生产的。

SHINE celebrates Ilumira's first anniversary with strong commercial growth, global expansion, EMA submission

SHINE庆祝Ilumira成立一周年，商业增长强劲、全球扩张、EMA提交

Post this

发布这个

Ilumira pairs with cancer-targeting molecules to deliver radiation directly to tumors, offering patients a more focused and less harmful way to treat cancer. SHINE is one of the only U.S.-based manufacturers of this critical isotope, and its proven reliability and high purity are earning trust across the global nuclear medicine community..

Ilumira 与靶向癌细胞的分子结合，将辐射直接递送到肿瘤，为患者提供一种更集中且伤害较小的癌症治疗方法。SHINE 是美国少数几家生产这种关键同位素的制造商之一，其可靠的性能和高纯度赢得了全球核医学界的信任。

'What excites me most about Ilumira's first year is knowing it's already making a difference for cancer patients around the world,' said

“伊鲁米拉（Ilumira）成立的第一年最让我兴奋的是，它已经在为世界各地的癌症患者带来改变，”

Greg Piefer

格雷格·皮费尔

, SHINE's founder and CEO. 'Every shipment represents hope. And with a global customer footprint, we're helping expand access to life-saving therapy with the quality and reliability this industry and these patients need.'

，SHINE的创始人兼首席执行官。“每一批货物都代表着希望。凭借全球客户的支持，我们正在帮助扩大获得救命治疗的机会，提供这个行业和这些患者所需的高质量和可靠性。”

Delivering Impact Through Precision and Performance

通过精确和性能产生影响

SHINE supplies Ilumira for usage at cancer treatment centers, in clinical trials, and at research institutions around the world. Customers include Blue Earth Therapeutics, WARF Therapeutics, the University of Wisconsin–Madison, and Cincinnati Children's Hospital. The company is also supporting the development of other targeted radiopharmaceuticals including from GlyTherix and from Antelope Surgical Solutions.

SHINE公司为世界各地的癌症治疗中心、临床试验和研究机构提供Ilumira产品。客户包括蓝地球治疗公司、WARF治疗公司、威斯康星大学麦迪逊分校以及辛辛那提儿童医院。该公司还支持其他靶向放射性药物的开发，包括来自GlyTherix和Antelope Surgical Solutions的药物。

Since its launch, Ilumira has helped advance breakthrough research, including a University of Wisconsin–Madison study that demonstrated a .

自推出以来，Ilumira 已帮助推进突破性研究，包括威斯康星大学麦迪逊分校的一项研究，该研究证明了 。

100% survival rate in kidney cancer models

肾癌模型中100%的存活率

with 8–20x greater efficacy in vivo compared to other compounds in development.

在体内相比其他在研化合物，其功效高8-20倍。

'The consistently high purity and reliability of SHINE's Lu-177 have allowed us to conduct our studies with a level of precision difficult to achieve before,' said Dr.

“SHINE的Lu-177始终如一的高纯度和可靠性使我们能够以之前难以达到的精确度进行研究，”博士表示。

Reinier Hernandez

雷内尔·埃尔南德斯

, Assistant Professor of Medical Physics and Radiology at the

医学物理与放射学助理教授

University of Wisconsin-Madison

威斯康星大学麦迪逊分校

.

。

Ilumira's consistent quality, high specific activity, and purity have established it as a best-in-class option for oncologists, radiopharma innovators, and researchers alike.

伊鲁米拉的一致质量、高比活性和纯度使其成为肿瘤学家、放射药物创新者和研究人员的首选。

Performance and Production at Scale

规模化的性能与生产

SHINE produces Ilumira at its Cassiopeia facility in

SHINE在仙后座工厂生产Ilumira

Janesville, Wisconsin

威斯康星州简斯维尔

with capacity for 100,000 doses per year and potential expansion to 200,000. The facility's consistent performance and scalable output ensure SHINE can meet rising demand for n.c.a. Lu-177 with confidence.

每年可生产10万剂，有潜力扩展到20万剂。该设施的持续稳定表现和可扩展的产量确保SHINE能够自信地满足市场对无载体添加Lu-177不断增长的需求。

Since its commercial debut, Ilumira has delivered:

自从它商业化 debut 以来，Ilumira 已经交付了：

Global Reach: customers in 19 countries and 4 continents

全球覆盖：遍布19个国家和4个大洲的客户

Reliability: >95% on-time, in-full delivery

可靠性：准时交货率超过95%，完整交付率高

Growth: strong revenue increase from 2024 to projected 2025

增长：从2024年到预计的2025年，收入将大幅增加。

Distribution: partnerships with Modawina Medical Company, Primo Biotech, and Sumitomo Corporation of Americas

分销：与Modawina医疗公司、Primo生物技术公司和住友美洲公司建立合作伙伴关系

Quality: High-purity product enabling breakthrough research and therapeutic progress

质量：高纯度产品，推动突破性研究和治疗进展

Strategic Expansion: EMA Application and SPECT Acquisition Announcement

战略扩张：EMA申请与SPECT收购公告

SHINE submitted a centralized Marketing Authorization Application to the European Medicines Agency (EMA) to market Ilumira across the EU and

SHINE 已向欧洲药品管理局 (EMA) 提交了集中化的营销授权申请，以在欧盟范围内上市 Ilumira。

entered a definitive agreement

达成了最终协议

to acquire the SPECT radiopharmaceutical division of Lantheus, a trusted provider of diagnostic isotopes used in millions of procedures each year. These two moves position the company as a comprehensive provider of therapeutic and diagnostic isotopes, expanding global access while accelerating commercialization of SHINE's growing product portfolio..

收购Lantheus的SPECT放射性药物部门，该公司是每年数百万次诊断程序中使用的诊断同位素的可靠供应商。这两项举措使该公司成为治疗性和诊断性同位素的综合供应商，扩大全球获取渠道，同时加速SHINE不断增长的产品组合的商业化进程。

The acquisition vertically integrates SHINE into the Tc-99m generator business and strengthens distribution for upcoming isotopes such as molybdenum-99. Together with the company's Chrysalis production facility, expected to begin operations as soon as 2027, SHINE is building a robust foundation for long-term leadership in nuclear medicine..

此次收购使SHINE垂直整合进入Tc-99m发生器业务，并加强了对即将推出的同位素（如钼-99）的分销能力。结合公司预计将于2027年投入运营的Chrysalis生产设施，SHINE正为在核医学领域的长期领导地位奠定坚实的基础。

SHINE's pipeline includes high-demand isotopes such as terbium-161 and molybdenum-99, supported by strategic U.S. and European partnerships. In 2024, the company secured

SHINE的生产管线包括铽-161和钼-99等高需求同位素，并得到美国和欧洲战略合作伙伴的支持。2024年，该公司确保了

$32 million

3200万美元

in funding from the U.S. Department of Energy's NNSA and €10.5 million alongside the University Medical Center Groningen to accelerate isotope development and supply.

来自美国能源部NNSA的资助以及与格罗宁根大学医学中心合作的1050万欧元，用于加速同位素的开发和供应。

About SHINE

关于SHINE

Headquartered in

总部位于

Janesville, Wisconsin

威斯康星州简斯维尔

, SHINE is an industry leader in next-generation fusion, developing innovative fusion-based technology that combines safety, cost-efficiency and environmental responsibility.

，SHINE 是下一代聚变领域的行业领导者，正在开发基于聚变的创新技术，该技术结合了安全性、成本效益和环境责任。

SHINE has successfully commercialized fusion across multiple applications, including neutron testing markets such as neutron radiography, radiation-effects testing and fusion material research. It has commercialized and is scaling its proprietary medical isotope production processes, supplying high-quality radioisotopes essential for procedures including diagnosing heart disease and cancer as well as cancer therapy..

SHINE已成功在多个应用领域实现聚变商业化，包括中子测试市场，如中子射线照相、辐射效应测试和聚变材料研究。该公司已经实现并正在扩展其专有的医用同位素生产流程，供应高质量的放射性同位素，这些同位素对于包括诊断心脏病和癌症以及癌症治疗在内的医疗程序至关重要。

Beyond these applications, SHINE is pioneering nuclear waste recycling to make nuclear energy more sustainable. Its long-term purpose is to change the way humans make energy by commercializing fusion energy. Unlike other fusion companies, SHINE takes a commercially driven path mirroring successful deep-tech industries.

除了这些应用之外，SHINE 正在开创核废料回收利用技术，以使核能更加可持续。其长期目标是通过商业化聚变能源改变人类的能源生产方式。与其他聚变公司不同，SHINE 采取了一条类似于成功深科技行业的商业化驱动路径。

Through this visionary approach, SHINE is advancing technology, healthcare, and sustainable energy, making a lasting impact across multiple sectors..

通过这一富有远见的方法，SHINE正在推动技术、医疗保健和可持续能源的发展，在多个领域产生持久影响。

SOURCE SHINE Technologies, LLC

源辉科技有限责任公司

WANT YOUR COMPANY'S NEWS

想要贵公司的新闻吗？

FEATURED ON PRNEWSWIRE.COM?

荣登PRNEWSWIRE.COM？

440k+

44万+

Newsrooms &

新闻编辑室 &

Influencers

影响者

9k+

9k+

Digital Media

数字媒体

Outlets

插座

270k+

27万+

Journalists

记者

Opted In

已选择加入

GET STARTED

开始使用